MedPath

The effect of finasteride for the treatment of melasma

Phase 3
Conditions
melasma.
Chloasma
Registration Number
IRCT2016031627077N1
Lead Sponsor
Ahwaz Jondishapur University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
30
Inclusion Criteria

inclusion criteria: patient with melasma and would like to participate in the study
exclusion criteria: pregnant and lactating women, patients treated with anti androgenic drugs, oral contraceptive use

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Melasma. Timepoint: Baseline, the end of the first month, the end of second month, the end of the third month. Method of measurement: By observing the amount of blur, uniformity and percentage of skin involvement in four areas of the forehead, right cheek, left cheek and chin.
Secondary Outcome Measures
NameTimeMethod
Satisfaction with treatment. Timepoint: end of treatment. Method of measurement: Interviews with patients.
© Copyright 2025. All Rights Reserved by MedPath